Microbial Consortium Composition for Gut Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory conditions, particularly those affecting the gut, are inadequate in modulating key physiological processes such as endocannabinoid metabolism and immune system activation, leading to suboptimal therapeutic outcomes.
Innovation Solution
A microbial consortium comprising two or more microorganisms, capable of modulating phospholipids, short chain fatty acids (SCFAs), lactate, secondary bile acids, polysaccharides, and glycosaminoglycans (GAGs), is administered to modulate these processes and enhance immune regulation, including the production of endocannabinoids like anandamide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for inflammatory conditions are used, then treatment is provided, but modulation of key physiological processes such as endocannabinoid metabolism and immune system activation is inadequate, leading to suboptimal therapeutic outcomes
Solution Approach 1:
The patent combines multiple bacterial strains into a consortium that works synergistically to modulate diverse physiological processes including endocannabinoid metabolism, immune system activation, and inflammation. This merging of multiple microorganisms creates a more versatile treatment that addresses multiple pathways simultaneously, resolving the contradiction between reliable therapeutic outcomes and adaptability to modulate various physiological processes.
Solution Approach 2:
The microbial consortium is designed to perform multiple functions: modulating endocannabinoid metabolism, regulating immune system activation, reducing inflammation, and maintaining gut integrity. This multi-functionality allows a single treatment to address multiple physiological processes, thereby improving both the reliability of therapeutic outcomes and the adaptability to modulate different physiological pathways.
2Adaptability or versatility
If a microbial consortium comprising two or more microorganisms is administered to modulate phospholipids, SCFAs, lactate, secondary bile acids, polysaccharides, and GAGs, then comprehensive treatment for inflammatory conditions is achieved, but treatment complexity increases
Solution Approach 1:
Multiple bacterial strains with complementary metabolic capabilities are merged into a single consortium formulation. This allows the complex treatment of multiple physiological processes to be delivered through a single administered product, reducing the practical complexity of treatment while maintaining comprehensive therapeutic capability.
Solution Approach 2:
The microbial consortium is designed to self-organize and self-regulate within the host environment, with each strain contributing specific metabolic functions that collectively address multiple physiological pathways. The system leverages the natural interactions and metabolic exchanges between strains to achieve comprehensive treatment without requiring complex external control mechanisms.
Data Source
AI summary
The present invention provides a microbial consortium comprising two or more microorganisms, compositions and kits comprising the same and uses thereof in methods of treating immune-related conditions.